| Identification | Back Directory | [Name]
2,5-Diazabicyclo[2.2.2]octane, 2-[6-[2-methoxy-5-(trifluoromethyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]- | [CAS]
2765254-39-3 | [Synonyms]
KRAS G12D inhibitor 14
2,5-Diazabicyclo[2.2.2]octane, 2-[6-[2-methoxy-5-(trifluoromethyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]- | [Molecular Formula]
C20H19F3N4OS | [MOL File]
2765254-39-3.mol | [Molecular Weight]
420.45 |
| Chemical Properties | Back Directory | [Boiling point ]
550.7±50.0 °C(Predicted) | [density ]
1.369±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
8.57±0.20(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a KD of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D[1]. | [in vivo]
KRAS G12D inhibitor 14 (compound KD-8) (40 mg/kg or 60 mg/kg; i.p.) exhibits significant antitumor efficacy in a CT26 tumor model with a tumor growth inhibition (TGI) of 42% or 53% without causing apparent toxicity[1]. | [IC 50]
KRas G12D: 33 nM (Kd) | [References]
[1] Li L, et al. Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. Eur J Med Chem. 2022;233:114243. DOI:10.1016/j.ejmech.2022.114243 |
|
|